

DAFTAR PUSTAKA

- Ahmed, M. (2015) 'Non-alcoholic fatty liver disease in 2015', *World Journal of Hepatology*, 7(11), pp. 1450–1459. doi: 10.4254/wjh.v7.i11.1450.
- Ahn, H. R. *et al.* (2014) 'The association between liver enzymes and risk of type 2 diabetes: The Namwon study', *Diabetology and Metabolic Syndrome*, 6(1), pp. 2–9. doi: 10.1186/1758-5996-6-14.
- American Diabetes Association (2020) '2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes-2020', *Diabetes care*, 43, pp. S14–S31. doi: 10.2337/dc20-S002.
- Anstee, Q. M., Targher, G. and Day, C. P. (2013) 'Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis', *Nature Reviews Gastroenterology and Hepatology*. Nature Publishing Group, 10(6), pp. 330–344. doi: 10.1038/nrgastro.2013.41.
- Ballestri, S. *et al.* (2016) 'Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis', *Journal of Gastroenterology and Hepatology (Australia)*, 31(5), pp. 936–944. doi: 10.1111/jgh.13264.
- Bhala, N., Ibrahim Kamal Jouness, R. and Bugianesi, E. (2013) 'Epidemiology and Natural History of Patients with NAFLD', *Current Pharmaceutical Design*, 19, pp. 5169–5176.
- Chalasan, N. *et al.* (2018) 'The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases', *Hepatology*, 67(1), pp. 328–357. doi: 10.1002/hep.29367.

- Chen, S. C. C. *et al.* (2017) 'Liver Fat, Hepatic Enzymes, Alkaline Phosphatase and the Risk of Incident Type 2 Diabetes: A Prospective Study of 132,377 Adults', *Scientific Reports*. Springer US, 7(1), pp. 1–9. doi: 10.1038/s41598-017-04631-7.
- Choi, J. H. *et al.* (2013) 'Increased risk of type 2 diabetes in subjects with both elevated liver enzymes and ultrasonographically diagnosed nonalcoholic fatty liver disease: A 4-year longitudinal study', *Archives of Medical Research*. Elsevier Inc, 44(2), pp. 115–120. doi: 10.1016/j.arcmed.2013.01.007.
- Critical Appraisal Skills Programme (CASP) (2018) *CASP Checklist: Cohort Study*, *Casp Uk*. Available at: www.casp-uk.net.
- Diabetes Federation International (2019) *IDF Diabetes Atlas 2019*, *International Diabetes Federation*. Available at: <http://www.idf.org/about-diabetes/facts-figures>.
- Dowman, J. K., Tomlinson, J. W. and Newsome, P. N. (2009) 'Pathogenesis of non-alcoholic fatty liver disease', *Qjm*, 103(2), pp. 71–83. doi: 10.1093/qjmed/hcp158.
- Dr Fauci, Longo, Kasper, Hauser, Jameson, L. (2017) *Harrison Principles of Internal Medicine 18th Ed, Methods*. doi: 10.1016/S1046-2023(16)30494-7.
- Dyson, J. K., Anstee, Q. M. and McPherson, S. (2014) 'Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging', *Frontline Gastroenterology*, 5(3), pp. 211–218. doi: 10.1136/flgastro-2013-100403.
- Fukuda, T. *et al.* (2016) 'The impact of non-alcoholic fatty liver disease on incident type 2 diabetes mellitus in non-overweight individuals', *Liver International*. doi: 10.1111/liv.12912.
- Gao, F. *et al.* (2019) 'Independent effect of alanine transaminase on the incidence

- of type 2 diabetes mellitus, stratified by age and gender: A secondary analysis based on a large cohort study in China', *Clinica Chimica Acta*. Elsevier, 495(2), pp. 54–59. doi: 10.1016/j.cca.2019.03.1636.
- Gastaldelli, A. and Cusi, K. (2019) 'From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options', *JHEP Reports*. Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL), 1(4), pp. 312–328. doi: 10.1016/j.jhepr.2019.07.002.
- Hashimoto, E., Tanai, M. and Tokushige, K. (2013) 'Characteristics and diagnosis of NAFLD/NASH', *Journal of Gastroenterology and Hepatology (Australia)*, 28(S4), pp. 64–70. doi: 10.1111/jgh.12271.
- Kementerian Kesehatan RI Badan Penelitian dan Pengembangan (2018) 'RISKESDAS 2018', *Kementrian Kesehatan Republik Indonesia*. doi: 1 Desember 2013.
- Kitchenham, B. (2004) 'Procedures for Performing Systematic Literature Reviews', *Joint Technical Report, Keele University TR/SE-0401 and NICTA TR-040001IT.1*, 33.
- Koliaki, C. *et al.* (2015) 'Adaptation of Hepatic Mitochondrial Function in Humans with Non-Alcoholic Fatty Liver Is Lost in Steatohepatitis', *Cell Metabolism*. doi: 10.1016/j.cmet.2015.04.004.
- Labrecque, D. R. *et al.* (2014) 'World gastroenterology organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis', *Journal of Clinical Gastroenterology*, 48(6), pp. 467–473. doi: 10.1097/MCG.000000000000116.
- Li, J. *et al.* (2019) 'Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: a systematic review and meta-analysis', *The Lancet Gastroenterology and Hepatology*. doi: 10.1016/S2468-1253(19)30039-1.

- Lonardo, A. *et al.* (2016) 'Fatty liver is associated with an increased risk of diabetes and cardiovascular disease-Evidence from three different disease models: NAFLD, HCV and HIV', *World Journal of Gastroenterology*. doi: 10.3748/wjg.v22.i44.9674.
- Mantovani, A. *et al.* (2018) 'Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: A meta-analysis', *Diabetes Care*, 41(2), pp. 372–382. doi: 10.2337/dc17-1902.
- Moher, D. *et al.* (2015) 'Evaluation of ASTM Standard Test Method E 2177, 6 Retroreflectivity of Pavement Markings in a Condition of 7 Wetness', *Systematic Reviews*, (January), pp. 1–9. doi: 10.1186/2046-4053-4-1.
- Nath, P. and Prasad Singh, S. (2016) 'Serum Transaminases: Quo Vadis', *Biochemistry & Analytical Biochemistry*, s3(1), pp. 1–3. doi: 10.4172/2161-1009.1000260.
- Oh, R. C. *et al.* (2017) 'Mildly Elevated Liver Transaminase Levels: Causes and Evaluation', *American family physician*, 96(11), pp. 709–715.
- Oka, R. *et al.* (2014) 'Elevated liver enzymes are related to progression to impaired glucose tolerance in Japanese men', *Diabetic Medicine*, 31(5), pp. 552–558. doi: 10.1111/dme.12345.
- Perkeni, P. (2019) 'Pedoman Pengelolaan dan Pencegahan Diabetes Mellitus Tipe 2 Dewasa di Indonesia'.
- Pitchumoni, C. S. (2012) 'Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)', *Geriatric Gastroenterology*, (June), pp. 399–407. doi: 10.1007/978-1-4419-1623-5_40.
- Qian, K. *et al.* (2015) 'Hepatic ALT isoenzymes are elevated in gluconeogenic conditions including diabetes and suppressed by insulin at the protein level', *Diabetes/Metabolism Research and Reviews*. doi: 10.1002/dmrr.2655.

- Rinella, M. E. (2015) 'Nonalcoholic fatty liver disease a systematic review', *JAMA - Journal of the American Medical Association*, 313(22), pp. 2263–2273. doi: 10.1001/jama.2015.5370.
- Schwartz, S. S. *et al.* (2016) 'The time is right for a new classification system for diabetes: Rationale and implications of the β -cell-centric classification schema', *Diabetes Care*. doi: 10.2337/dc15-1585.
- Schwenger, K. J. P. and Allard, J. P. (2014) 'Clinical approaches to non-alcoholic fatty liver disease', *World Journal of Gastroenterology*, pp. 1712–1723. doi: 10.3748/wjg.v20.i7.1712.
- Shen, X. *et al.* (2018) 'Nonalcoholic fatty liver disease and risk of diabetes: A prospective study in China', *Endocrine Practice*, 24(9), pp. 823–832. doi: 10.4158/EP-2018-0098.
- Soelistijo, S. A. *et al.* (2015) *Konsensus Pengendalian dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia 2015*, Perkeni. doi: 10.1017/CBO9781107415324.004.
- Sporea, I. *et al.* (2009) 'The value of transabdominal ultrasound for assessment of the severity of liver steatosis as compared to liver biopsy', *Central European Journal of Medicine*. doi: 10.2478/s11536-009-0067-9.
- Tjokroprawiro, A. *et al.* (2015) *Buku ajar ilmu penyakit dalam. Ed.2: Fakultas Kedokteran Universitas ... - Google Buku, Perpustakaan Nasional RI*.
- Wong, S.-W. and Chan, W.-K. (2020) 'Epidemiology of non-alcoholic fatty liver disease in Asia', *Indian Journal of Gastroenterology*, 39(1), pp. 1–8. doi: 10.1007/s12664-020-01018-x.
- Xia, M. F., Bian, H. and Gao, X. (2019) 'NAFLD and Diabetes: Two Sides of the Same Coin? Rationale for Gene-Based Personalized NAFLD Treatment', *Frontiers in Pharmacology*, 10(JULY), pp. 1–11. doi: 10.3389/fphar.2019.00877.

- Xu, L. *et al.* (2015) 'Liver enzymes and incident diabetes in China: A prospective analysis of 10 764 participants in the Guangzhou Biobank Cohort Study', *Journal of Epidemiology and Community Health*, 69(11), pp. 1040–1044. doi: 10.1136/jech-2015-205518.
- Yki-Järvinen, H. (2014) 'Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome', *The Lancet Diabetes and Endocrinology*. doi: 10.1016/S2213-8587(14)70032-4.
- Zhang, J. *et al.* (2018) 'Liver Enzymes, Fatty Liver and Type 2 Diabetes Mellitus in a Jinchang Cohort: A Prospective Study in Adults', *Canadian Journal of Diabetes*. Elsevier Inc., 42(6), pp. 652–658. doi: 10.1016/j.jcjd.2018.02.002.